BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Woodhouse CA, Patel VC, Goldenberg S, Sanchez-Fueyo A, China L, O'Brien A, Flach C, Douiri A, Shawcross D. PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis: study protocol for a single-blinded trial. BMJ Open 2019;9:e023518. [PMID: 30772848 DOI: 10.1136/bmjopen-2018-023518] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Bloom PP, Tapper EB, Young VB, Lok AS. Microbiome therapeutics for hepatic encephalopathy. J Hepatol 2021;75:1452-64. [PMID: 34453966 DOI: 10.1016/j.jhep.2021.08.004] [Reference Citation Analysis]
2 Woodhouse C, Singanayagam A, Patel VC. Modulating the gut-liver axis and the pivotal role of the faecal microbiome in cirrhosis. Clin Med (Lond) 2020;20:493-500. [PMID: 32934044 DOI: 10.7861/clinmed.2020-0676] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Kronborg TM, Ytting H, Hobolth L, Møller S, Kimer N. Novel Anti-inflammatory Treatments in Cirrhosis. A Literature-Based Study. Front Med (Lausanne) 2021;8:718896. [PMID: 34631742 DOI: 10.3389/fmed.2021.718896] [Reference Citation Analysis]
4 Skinner C, Thompson AJ, Thursz MR, Marchesi JR, Vergis N. Intestinal permeability and bacterial translocation in patients with liver disease, focusing on alcoholic aetiology: methods of assessment and therapeutic intervention. Therap Adv Gastroenterol 2020;13:1756284820942616. [PMID: 33149761 DOI: 10.1177/1756284820942616] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Hatton GB, Ran S, Tranah TH, Shawcross DL. Lessons Learned from Faecal Microbiota Transplantation in Cirrhosis. Curr Hepatology Rep 2020;19:159-67. [DOI: 10.1007/s11901-020-00520-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
6 Mullish BH, Quraishi MN, Segal JP, Ianiro G, Iqbal TH. The gut microbiome: what every gastroenterologist needs to know. Frontline Gastroenterol 2021;12:118-27. [PMID: 33613943 DOI: 10.1136/flgastro-2019-101376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Woodhouse CA, Patel VC, Goldenberg S, Sanchez-Fueyo A, China L, O'Brien A, Flach C, Douiri A, Shawcross D. PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis: study protocol for a single-blinded trial. BMJ Open 2019;9:e023518. [PMID: 30772848 DOI: 10.1136/bmjopen-2018-023518] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
8 Hoilat GJ, Suhail FK, Adhami T, John S. Evidence-based approach to management of hepatic encephalopathy in adults. World J Hepatol 2022; 14(4): 670-681 [DOI: 10.4254/wjh.v14.i4.670] [Reference Citation Analysis]
9 Jin CY, Hu Y, Jin B. Faecal microbiota transplantation: Application in treatment of some digestive diseases and safety concerns. Shijie Huaren Xiaohua Zazhi 2020; 28(4): 135-143 [DOI: 10.11569/wcjd.v28.i4.135] [Reference Citation Analysis]
10 Merrick B, Robinson E, Bunce C, Allen L, Bisnauthsing K, Izundu CC, Bell J, Amos G, Shankar-Hari M, Goodman A, Shawcross DL, Goldenberg SD. Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms (FERARO): a prospective, randomised placebo-controlled feasibility trial. BMJ Open 2020;10:e038847. [PMID: 32457083 DOI: 10.1136/bmjopen-2020-038847] [Reference Citation Analysis]
11 Hassouneh R, Bajaj JS. Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment. J Clin Med 2021;10:330. [PMID: 33477417 DOI: 10.3390/jcm10020330] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
12 Maraolo AE, Scotto R, Zappulo E, Pinchera B, Schiano Moriello N, Nappa S, Buonomo AR, Gentile I. Novel strategies for the management of bacterial and fungal infections in patients with liver cirrhosis: focus on new antimicrobials. Expert Rev Anti Infect Ther 2020;18:191-202. [PMID: 32011191 DOI: 10.1080/14787210.2020.1725473] [Reference Citation Analysis]
13 Patel VC, Williams R. Antimicrobial resistance in chronic liver disease. Hepatol Int. 2020;14:24-34. [PMID: 31797303 DOI: 10.1007/s12072-019-10004-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
14 Gu X, Lu Q, Zhang C, Tang Z, Chu L. Clinical Application and Progress of Fecal Microbiota Transplantation in Liver Diseases: A Review. Semin Liver Dis 2021. [PMID: 34261137 DOI: 10.1055/s-0041-1732319] [Reference Citation Analysis]
15 Moreno-Gonzalez M, Beraza N. The Role of the Microbiome in Liver Cancer. Cancers (Basel) 2021;13:2330. [PMID: 34066064 DOI: 10.3390/cancers13102330] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
16 Eriksen LL, Baunwall SMD, Eriksen PL, Bak-fredslund KP, Nielsen JE, Dahlerup JF, Thomsen KL, Vilstrup H, Hvas CL. Deep hyperammonemic hepatic encephalopathy precipitated by fecal microbiota transplantation for fulminant Clostridioides difficile infection. Gastroenterology Report 2021. [DOI: 10.1093/gastro/goab043] [Reference Citation Analysis]
17 Sehgal R, Bedi O, Trehanpati N. Role of Microbiota in Pathogenesis and Management of Viral Hepatitis.Front Cell Infect Microbiol. 2020;10:341. [PMID: 32850467 DOI: 10.3389/fcimb.2020.00341] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
18 Keskey R, Cone JT, DeFazio JR, Alverdy JC. The use of fecal microbiota transplant in sepsis.Transl Res. 2020;226:12-25. [PMID: 32649987 DOI: 10.1016/j.trsl.2020.07.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]